ORGO Organogenesis Holdings (A)

Organogenesis Announces Annual College Scholarship Award Winner

Organogenesis Announces Annual College Scholarship Award Winner

Baylah Mazonson, 2019 Regenerative Medicine Scholarship Recipient, Will Attend Boston University This Fall

CANTON, Mass., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the winner of its 2019 Canton High School Regenerative Medicine Scholarship Award. 

This year’s $5,000 scholarship winner is Baylah Mazonson, a member of the Canton High School graduating class of 2019. She will attend Boston University in the fall to major in biology. 

“I can’t express how honored I am to be awarded with this scholarship,” Ms. Mazonson said. “I want to thank Organogenesis for supporting me with this incredible opportunity as I pursue my goal of becoming a clinical researcher.” 

The annual scholarship is awarded to a graduating senior from Canton High School whose achievements and interest in pursuing a career in medicine, biomedical engineering or the life sciences establish them as a potential future leader in the medical field.

Along with a slew of academic achievements, among them official commendation from the National Merit Scholarship Corporation, Ms. Mazonson is also an accomplished athlete and musician. She was a member of both the varsity swim team and the school orchestra. 

“Each year Organogenesis awards this scholarship to a talented, accomplished and driven student like Baylah with a passion for the life sciences,” said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis. “We are proud to support Baylah’s pursuit of her career goals and her commitment to improving the lives of patients.”

In addition to academic achievement, the Organogenesis scholarship is awarded based on participants’ response to the essay question, “How do you see yourself contributing to the future of the life sciences?” Ms. Mazonson responded by discussing how her interest in science extends beyond academics. Growing up, two members of her family were diagnosed with multiple sclerosis (MS). Following the diagnoses, Ms. Mazonson was motivated to pursue a career in clinical medicine with the hopes of someday helping her family and millions of other patients who live with chronic conditions.

For more information on the Canton High School Regenerative Medicine Scholarship Award, please visit:

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit .

Press and Media Inquiries:
 Angelyn Lowe
  
 781-774-9364

Investor Inquiries:
 Westwicke Partners
 Mike Piccinino, CFA
  
 443-213-0500
EN
06/09/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Organogenesis Holdings (A)

 PRESS RELEASE

Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Resu...

Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2025. Fourth Quarter 2025 Financial Results Summary: Net product revenue of $225.1 million ...

 PRESS RELEASE

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2...

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026 CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2025 financial results will be reported after the market closes on Thursday, February 26th. Management will host a conference call at 5:00 p.m....

 PRESS RELEASE

Organogenesis Announces Initiation of Biologics License Application fo...

Organogenesis Announces Initiation of Biologics License Application for ReNu® Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026 CANTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the initiation of a rolling submission of a Biologics License Application (BLA) to the Food and Drug Administ...

 PRESS RELEASE

Organogenesis Announces Successful FDA Meeting and Plan to File BLA fo...

Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain Clinical Development Program Appropriate for Rolling BLA  Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the successful completion of a planned Type-B meeting with the Food and Drug Administra...

 PRESS RELEASE

Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Resul...

Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance CANTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results Summary: Net product revenue of $150.5 million for the third quarter o...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch